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Bullous lupus erythematosus is an autoantibody-
mediated subepidermal blistering disease that occurs
in patients with systemic lupus erythematosus
(SLE).1 Erythema gyratum repens (EGR) is a clinical
diagnosis characterized by a wood grain pattern of
centrifugally migrating erythematous plaques with
fine leading scale. Although most cases of EGR are
associated with underlying malignancy, several
nonparaneoplastic-associated cases of EGR have
been reported.2 Here, we report on a patient with
bullous lupus erythematosus presenting in an EGR
pattern.REPORT OF CASE
Apreviouslyhealthy55-year-oldAfrican-American
man presented for evaluation of a sudden-onset,
diffuse vesiculobullous eruption affecting the trunk
and extremities. The patient denied associated skin
pain or pruritus. He was otherwise well, and a
detailed review of systems was negative. He had a
medical history of hypertension, hyperlipidemia, and
diabetes mellitus type II. His medications included
atorvastatin, methocarbamol, and calcium/vitamin D
supplementation. He had no known drug allergies or
family history of autoimmune disease.
Initial physical examination found erythematous
plaques expanding centrifugally with peripheral
tense vesicles and bullae (Fig 1). Over a period of
days, concentric vesicular plaques developed (Fig 2).
There was no mucosal involvement.
Histopathologic examination found a superficial
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and numerous neutrophils. Neutrophilic microab-
scesses were present within the papillary dermis.
The neutrophilic infiltrate extended into the over-
lying epidermis with vacuolar alteration of the basal
layer. A second specimen showed a subepidermal
bulla with epidermal necrosis, lichenoid interface
dermatitis, and a polymorphous dermal infiltrate.
Direct immunofluorescence was strongly positive
for C3 (41) granular deposition and shaggy linear
fibrin (41) at the dermal-epidermal junction.
Granular IgG was present focally at the dermal-
epidermal junction.
Serologic testing found positive antinuclear anti-
body, 1:1280 titer in a speckled pattern, antiedou-
ble-strandedDNA antibody (14), anti-Smith antibody
([8.0), and antiribonucleoprotein antibody ([8.0).
Anti-Ro and anti-La antibodies were not present.
Serum C3 was low (76 mg/dL), and C4 was within
normal limits. Results of complete blood count with
differential, comprehensive metabolic panel, and
urinalysis were within normal limits.
Serologic, histopathologic, and direct immuno-
fluorescence findings supported a diagnosis of
bullous lupus erythematosus. Given the concentric
morphology of the eruption, a diagnosis of an EGR
variant of bullous lupus erythematosus was made.
Because of the association of EGR with malignancy,JAAD Case Reports 2016;2:111-3.
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Fig 1. Posterior shoulder and back with erythematous
plaques and peripheral tense vesicles and bullae in a
centrifugal pattern.
Fig 2. Abdomen and chest with multiple concentric
vesicular plaques.
Fig 3. Back with concentric patches of postinflammatory
hypopigmentation 2 weeks after starting dapsone.
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results of which were negative.
Initial treatment included oral prednisone mono-
therapy in doses of 60 mg/d without improvement.
Addition of dapsone, 25 mg/d, resulted in completeresolution of the eruption within 2 weeks with
subsequent postinflammatory hypopigmentation in
concentric patches (Fig 3). Oral prednisone was
tapered and discontinued. His treatment course
was complicated by hemolytic anemia necessitating
the discontinuation of dapsone. Mycophenolate
mofetil, 1500 mg twice daily, was initiated, and he
has remained clear to date.
DISCUSSION
Bullous lupus erythematosus is an SLE variant
characterized by rapid onset of tense vesiculobullous
lesions typically in a photodistributed pattern on the
face, trunk, and upper extremities. Less commonly,
lesions can appear on mucous membranes and
nonephoto-exposed skin.1,3Affected patients usually
experience constitutional symptoms of SLE inclu-
ding fever, fatigue, weight loss, and arthralgia.
Histopathology findings show subepidermal vesicu-
lation, neutrophilic microabscesses in the papillary
dermis, mucin deposition in the dermis, dermal
edema, and absence of eosinophils. Direct immuno-
fluorescence shows IgG, IgA, IgM, and complement
components at the dermal-epidermal junction in a
granular or linear pattern. Depositions can be focal or
continuous and may extend into the dermis and
perivascular region.4Most patientswith bullous lupus
erythematosus have a positive antinuclear antibody
and frequently will have positive antiedouble-
stranded DNA antibody and antiecollagen type VII
antibody.5 First-line treatment of bullous lupus ery-
thematosus is with dapsone, although it is contra-
indicated in patients with glucose-6-phosphate
dehydrogenase deficiency. Dapsone results in cessa-
tion of new blister formation within days for most
patients.6 Prednisone is used as an alternative or
adjunct, especially for patients that require treatment
for concomitant systemicmanifestations of SLE.Other
treatment options include rituximab, methotrexate,
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data on their use are limited.1 Lesions heal without
scarring but often with evident postinflammatory
hypopigmentation or hyperpigmentation.7
The presented patient met 2012 Systemic Lupus
International Collaborating Clinics criteria for diag-
nosis of SLE and had immunohistopathologic and
clinical evidence of bullous lupus, with blisters
developing in a wood grain, concentric morphology
reminiscent of EGR. EGR is a clinical entity with
nonspecific histopathologic findings. Most patients
are found to have an associated malignancy; there-
fore, affected patients must undergo malignancy
workup.2 Other diseases including lepromatous
leprosy, limited systemic sclerosis, and psoriasis are
reported to present in an EGR pattern.2,7 Finally,
there is an entity known as lupus erythematosus
gyratus repens, a rare variant of subacute cutaneous
lupus erythematosus, which was a diagnostic consid-
eration in this case. In this entity, lesions typically
present as widespread, concentric, erythematous
plaques, often with double-contoured edges. The
plaques are often moderately to deeply infiltrated
with overlying crusted erosions and scaling.
Histopathologic characteristics include hydropic
degeneration of the basal layer, keratinocyte necro-
sis, and atrophy of the epidermis.8
To our knowledge, blisters of bullous lupus ery-
thematosus presenting in a centrifugally expanding,
concentric pattern are not reported. There is 1 report
of infiltrated erythematous plaques arranged in an
EGR-like pattern in a patient with SLE.9 Another
patient with SLE had leukocytoclastic vasculitis in an
EGR-like pattern. Histopathologic findings includeda neutrophil predominant vasculitis.10 These find-
ings appear to be similar clinical entities. We suspect
that the EGR-like pattern in patients with SLE,
and forms of SLE such as bullous lupus erythemato-
sus, may be an uncommon morphology that is
associated with a neutrophilic predominance on
histopathology.
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